The fund has no exact preference in some founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Mobile Apps, Biotechnology. Among the various public portfolio startups of the fund, we may underline CMAB BioPharm, Dadabus Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund.
The typical case for the fund is to invest in rounds with 2-3 participants. The meaningful sponsors for the fund in investment in the same round are Qianhai Fund of Funds, Northern Light Venture Capital, C-Bridge Capital. In the next rounds fund is usually obtained by Tigermed, Qianhai Fund of Funds, Cormorant Capital.
The important activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund.
| Fund Name | Location |
| Aegis Venture Funds | New York, New York, United States |
| Alvin Fund | - |
| Booking Holdings | Connecticut, Norwalk, United States |
| Bridge Global Capital | New York, New York, United States |
| C9 Capital | - |
| Chengdu Caiyun Nongye | Chengdu, China, Sichuan |
| Cliffs | Luxembourg, Luxembourg |
| Communications Equity Associates | Florida, Tampa, United States |
| CyberSmart Angels | - |
| FCMB Capital Markets | Lagos, Lagos, Nigeria |
| Hewlett Packard Pathfinder | California, Palo Alto, United States |
| HNA Capital | Beijing, Beijing, China |
| Joincare Pharmaceutical | China, Guangdong, Shenzhen |
| Performance Equity Management | Connecticut, Greenwich, United States |
| Purple Arch Ventures | Chicago, Illinois, United States |
| Sealand Capital | Denmark, Københoved, Syddanmark |
| Swiss Entrepreneurs Fund | Switzerland, Zürich, Zurich |
| TRANSIT GENERAL OFFICE | Japan, Tokyo |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
CMAB BioPharm | $38M | 02 Jan 2018 | Gusu District, Jiangsu, China | ||
Dadabus | $32M | 30 Sep 2015 | Futian District, Guangdong Province |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
CMAB BioPharm | $38M | 02 Jan 2018 | Gusu District, Jiangsu, China | ||
Dadabus | $32M | 30 Sep 2015 | Futian District, Guangdong Province |
